Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis--a double-blind placebo controlled study
Lau CS, Morley KD, Belch JJ
British journal of rheumatology · 81 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 1993-01-01 · Br J Rheumatol · vol. 32 · número 11 · págs. 982–989
- Editorial
- Oxford University Press
- Citado
- 161 citas · más que el 87% de estudios similares · 2.0× el promedio de su campo
- Referencias
- 0 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Rheumatoid Arthritis Research and Therapies · Inflammatory mediators and NSAID effects
- Palabras clave
- fish oil supplementation, rheumatoid arthritis, eicosapentaenoic acid, docosahexaenoic acid, anti-inflammatory activity, prostaglandins, leukotrienes, arachidonic acid metabolism, long-term treatment
- MeSH
- erythrocyte membrane, humans, arthritis, rheumatoid, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, fatty acids, fish oils, anti-inflammatory agents, non-steroidal, drug combinations, double-blind method, middle aged, patient satisfaction, female, male
3 autores
- Chak Sing Lau🇬🇧 · autor de correspondenciaNinewells Hospital
- Kenneth D. Morley🇬🇧Ninewells Hospital
- J. J. F. Belch🇬🇧Ninewells Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Maxepa contains eicosapentaenoic acid (EPA) (171 mg/capsule) and docosahexaenoic acid (DHA) (114 mg/capsule). EPA acts as an alternative substrate to arachidonate, leading to the formation of the less proinflammatory prostaglandins ('3' series) and leukotrienes ('5' series). If Maxepa has anti-inflammatory properties it could be expected to reduce the requirement for NSAIDs in patients with RA. This has not been investigated nor has Maxepa therapy been studied over a full 1-yr period. Sixty-four patients with stable RA requiring NSAID therapy only were studied. Patients received either 10 Maxepa or air-filled placebo capsules per day for 12 months. All then received placebo capsules for a further 3 months. Patients were reviewed at 3-monthly intervals. NSAID requirement at entry visit for each patient was assigned as 100%. Patients were instructed to slowly reduce their NSAID dosage providing there was no worsening of their symptoms. Clinical and laboratory parameters of RA activity were also measured. There was a significant reduction in NSAID usage in patients on Maxepa when compared with placebo from month 3 [mean (95% C.I. for mean) requirement--71.1 (55.9-86.2)% and 89.7 (73.7-105.7)%, respectively]. This effect reached its maximum at month 12 [40.6 (24.5-56.6)% and 84.1 (62.7-105.5)%, respectively] and persisted to month 15 [44.7 (27.6-61.8)% and 85.8 (60.5-111.1)%, respectively] (P < 0.001, ANOVA). These patients were able to reduce their NSAID requirement without experiencing any deterioration in the clinical and laboratory parameters of RA activity.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.